Exchange: NASDAQ·Updated 04:07 AM EDT
LXEO logo

LXEO Lexeo Therapeutics Inc.

$4.96
$0.18
(3.77%)
Pre-Market
Prev Close $4.78
Reported EarningsAug 12
Mkt Cap$385.62M
Vol14.00

About LXEO

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
39

Bearish Sentiment

How do you feel about LXEO?

Advertisement|Remove ads.